Price
8.29
+1.71%52W Range
Market Cap
₹72.46 Cr
Traded: ₹0.02 Cr (0.03%) 0.0x
Free Float: ₹45.34 Cr (0.04% of FF traded)
Volume · 60D trend
21.99 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +0.0% | +0.0% | +6.0% | -- | +11.0% | Accelerating |
| Profit | +4.0% | -- | -- | -- | +90.0% | Accelerating |
| Return | -11.0% | -14.0% | -19.0% | -36.0% | -- | Decelerating |
| ROE | +2.0% | -1.0% | -5.0% | -- | -- | Decelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 33 | 23 | 22 | 23 | 25 | 23 | 20 | 24 | 22 | 14 | 19 | 16 | 22 | 22 | 21 |
| Expenses | 28 | 34 | 22 | 21 | 22 | 31 | 22 | 21 | 23 | 21 | 14 | 19 | 18 | 25 | 24 | 23 |
| Operating Profit | 2 | -2 | 2 | 1 | 2 | -5 | 0 | -1 | 2 | 1 | -0 | 0 | -2 | -4 | -2 | -2 |
| OPM % | 6.8% | -5.0% | 7.2% | 4.1% | 7.1% | -21.4% | 1.1% | -4.3% | 8.1% | 3.9% | -0.4% | 2.2% | -13.3% | -16.4% | -10.0% | -9.4% |
| Other Income | 0 | 1 | 1 | 1 | 1 | -1 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | -12 | 1 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 |
| Profit Before Tax | 0 | -3 | 0 | -0 | 1 | -9 | -2 | -2 | 0 | 0 | 1 | -1 | -3 | -17 | -3 | -1 |
| Tax % | -1716.7% | 19.7% | -887.5% | 1800.0% | -69.3% | -23.1% | 15.8% | 398.1% | 415.0% | 516.7% | 100.0% | -26.3% | -18.4% | -36.4% | -4.8% | -13.2% |
| Net Profit | 1 | -4 | 1 | -0 | 1 | -7 | -2 | -10 | -1 | -1 | 0 | -1 | -3 | -11 | -3 | -1 |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -19 | 0 | 0 |
| EPS (Rs) | 0.1 | -0.4 | 0.1 | -0.0 | 0.1 | -0.8 | -0.2 | -1.2 | -0.1 | -0.1 | 0.0 | -0.1 | -0.4 | -1.6 | -0.4 | -0.1 |
| Sales Growth (YoY) | 29.6% | 29.9% | 2.7% | 13.2% | -4.2% | 16.2% | 58.5% | 4.0% | 54.0% | -0.3% | -35.6% | -10.1% | -25.4% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 40.5% | 4.4% | -5.0% | -6.8% | 11.1% | 15.1% | -19.6% | 13.0% | 51.5% | -24.5% | 19.1% | -26.8% | -2.1% | 5.4% | -- |
| OP Growth (YoY) | 24.7% | 69.5% | 568.0% | 208.3% | -15.7% | -740.5% | 516.7% | -304.9% | 192.9% | 123.6% | 97.3% | 120.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | 226.2% | -198.2% | 83.5% | -45.2% | 130.9% | -2252.0% | 129.8% | -142.6% | 134.5% | 1500.0% | -114.6% | 119.3% | 40.4% | -60.4% | -12.7% | -- |
| Profit Growth (YoY) | 2.8% | 12.9% | 142.9% | 98.1% | 268.3% | -446.7% | -18500.0% | -1313.7% | 75.7% | -109.5% | 100.4% | 20.6% | 32.7% | 281.6% | -1122.0% | -441.0% |
| EPS Growth (YoY) | -- | 49.4% | 142.9% | 98.3% | 250.0% | -710.0% | -- | -1244.4% | 80.0% | 93.9% | 100.0% | 35.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -555.6% | 550.0% | -116.7% | 114.8% | -285.7% | 82.6% | -1412.5% | 20.0% | -- | 100.0% | 77.5% | 75.8% | -283.7% | -207.1% | -- |
| OP Margin | -- | -5.0% | 7.2% | 4.1% | 7.1% | -21.4% | 1.1% | -4.3% | 8.1% | 3.9% | -0.4% | 2.2% | -13.3% | -16.4% | -10.0% | -9.4% |
| Net Margin | -- | -10.9% | 3.4% | -0.9% | 4.5% | -27.6% | -8.1% | -52.4% | -2.6% | -3.5% | 0.1% | -3.9% | -16.3% | -49.3% | -12.4% | -4.4% |
| Material Cost % | 66.0% | 76.0% | 58.0% | 59.0% | 59.0% | 77.0% | 62.0% | 67.0% | 59.0% | 68.0% | 54.0% | 57.0% | 70.0% | 71.0% | 73.0% | 69.0% |
| Employee Cost % | 9.0% | 10.0% | 12.0% | 12.0% | 11.0% | 9.0% | 12.0% | 13.0% | 10.0% | 11.0% | 17.0% | 10.0% | 15.0% | 9.0% | 13.0% | 13.0% |
| P/S | 0.66 | 0.78 | 0.83 | 0.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.42 | 0.46 | 0.45 | 0.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper Publication of Un- Audited Financial Results for the Quarter Ended June 30, 2026.
Statement of Deviation and Variation for the Quarter Ended 30th June, 2026
The Board of Directors approved the Un-Audited Financial Results for the Quarter Ended 30th June, 2026
The Board of Directors in its meeting held on 11th August, 2026 inter alia Considered and Approved the Un-Audited Financial Results for the Quarter Ended 30th June, 2026
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Un-Audited Financial ....
Voting Results and Scrutinizer Report of Postal Ballot of the company concluded on 29 July, 2026.
Proceedings of Postal Ballot by Remote E-Voting Process by Members of the Company concluded on July 29, 2026.
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Newspaper Publication of Postal Ballot Notice dated 29 June 2026.
Notice of Postal Ballot
Outcome of Board meeting regarding variation in the utilization of proceeds raised through preferential issue as approved by shareholders through postal ballot on June 23, 2025.
Intimation of closure of Trading Window for Quarter ended June 30, 2026.
Newspaper Publication of Audited Financial Results for Quarter and Year ended March 31, 2026
Audited Financial Result for quarter and year ended 31 March, 2026.
Statement of Deviation for Quarter ended 31 March, 2026.
The Board of Directors of the company inter alia, considered and approved the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2025 today in its ....
Annual Secretarial Compliance report for the Year Ended 31st March, 2026
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Audited Financial ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Intimation under regulation 7 and 30 of SEBI (LODR) Regulation , 2015, the Company has entered into a tripartite Agreement between issuer, Old RTA and New RTA on dated 27.04.2026
JHS Svendgaard Laboratories Limited informs Compliance Certificate under Regulation 74(5) of SEBI (Depositories Participants) Regulation , 2018.
Update on the change of Registrar and Transfer Agent(RTA)
Newspaper Publication in Support of Investor Education Protection Fund Authority second 100 days campaign
Copy of Newspaper Publication for opening of Single Window for Re-Lodgment of transfer requests of Physical Shares as per the SEBI Circular dated January 30, 2026.
Intimation of closure of Trading Window for the Quarter and Year Ended March 31, 2026.
Newspaper Publication of Financial Result for Quarter and Nine months ended 31 December, 2025.
To considered and approved the Un-Audited Financial Results for the Quarter and Nine Month Ended 31st December, 2025
The Board of Director Considered and approved the Un-Audited Financial Results for the Quarter Ended 31st December, 2025
Statement of Deviation or variation for the Quarter ended 31st December, 2025
The Board of directors in its meeting held on 10th February, 2025 , approved the appointment of Internal Auditor
Intimation of Grant of ESOP under JHS Svendgaard Laboratories Limited Employee Option Scheme 2025.
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 ,inter alia, to consider and approve the un-audited ....
The Board of Directors at their meeting held on 01st February, 2026 approved the allotment of 1801801 equity shares at an issue price 27.75 through conversion of warrants
Compliance Certificate under Regulation 74(5) of DP Regulations, 2015 for the quarter ended December 31, 2025.
Intimation of Closure of Trading Window for the Quarter ended December 31, 2025.
Intimation of Special Window for Re-lodgement of transfer request of Physical shares as per SEBI Circular dated July 02, 2025.
Newspaper Publication of Financial Results for quarter and half year ended 30 September, 2025
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve un-audited financial ....
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve un-audited Financial ....
INTIMATION OF WARNING LETTER ISSUED BY THE STOCK EXCHANGES ON 14TH OCTOBER, 2025.
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2025.
Intimation of Closure of Trading Window for quarter and half year ended 30 September, 2025.
Approval of JHS Svendgaard Laboratories Limited ESOP Scheme, 2025 in 21st Annual General Meeting held on 20.09. 2025
Re-appointment of Mr. Nikhil Nanda as Managing Director in the AGM held on 20th September, 2025
Appointment of Secretarial Auditor for the 5 year commencing form 21st AGM, held on 20th September, 2025, till the conclusion of 26th AGM
Appointment of Statutory Auditors for the period of 5 years commencing from conclusion of 21st AGM till the conclusion of 26th AGM to be held in 2030
Intimation of Scrutinizer report for the 21st AGM of the Company held on 20th September, 2025
Enclose the Summary of Proceedings of the 21st Annual General Meeting of the Company held on 20 September, 2025 through VC/OAVM.
Intimation of Newspaper Publication regarding the initiation of 100 days campaign named "Saksham Niveshak".
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 the company has launched 100 days campaign titled Saksham Niveshak
Annual Reports
15Concalls
9May 2024
31 May 2024Nov 2023
30 Nov 2023Jun 2023
30 Jun 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021